Orexo Stock

Orexo EBIT

The EBIT of Orexo (ORX.ST) as of Aug 10, 2026 is -352.90 M SEK. In the previous year, EBIT was -140.30 M SEK — a change of 151.53% (lower).

EBIT

-352.90 MSEK

YoY

151.53%

Last updated:

In 2026, Orexo's EBIT was -352.90 M SEK, a 151.53% increase from the -140.30 M SEK EBIT recorded in the previous year.

The Orexo EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M SEK)
Date
EBIT (M SEK)
Jan 1, 2021
-194.30 base
Jan 1, 2022
-183.90 base
Jan 1, 2023
-99.10 base
Jan 1, 2024
-140.30 base
Jan 1, 2025
-352.90 base
Jan 1, 2026 (e)
-7.41 base
Jan 1, 2027 (e)
-10.52 base
Jan 1, 2028 (e)
-12.86 base
YEAREBIT (M SEK)
2028 est -12.86
2027 est -10.52
2026 est -7.41
2025 -352.90
2024 -140.30
2023 -99.10
2022 -183.90
2021 -194.30
2020 -25.10
2019 231.20
2018 95.80
2017 57.40
2016 51.70
2015 -168.99
2014 -25.01
2013 -139.69
2012 -79.41
2011 -391.50
2010 -81.77
2009 -99.08
2008 -112.50
2007 -180.57
2006 -40.59
Access this data via the Eulerpool API

Orexo Revenue

Orexo Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
565.00 M SEK
-194.30 M SEK
-223.50 M SEK
Jan 1, 2022
624.30 M SEK
-183.90 M SEK
-177.60 M SEK
Jan 1, 2023
638.80 M SEK
-99.10 M SEK
-128.30 M SEK
Jan 1, 2024
590.00 M SEK
-140.30 M SEK
-203.00 M SEK
Jan 1, 2025
26.00 M SEK
-352.90 M SEK
-129.80 M SEK
Jan 1, 2026 (e)
19.00 M SEK
-7.41 M SEK
-338.64 M SEK
Jan 1, 2027 (e)
27.00 M SEK
-10.52 M SEK
-252.08 M SEK
Jan 1, 2028 (e)
33.00 M SEK
-12.86 M SEK
-269.39 M SEK

Orexo Margins

Orexo stock margins

The Orexo margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Orexo. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Orexo.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
86.04 %
-34.39 %
-39.56 %
Jan 1, 2022
88.42 %
-29.46 %
-28.45 %
Jan 1, 2023
86.08 %
-15.51 %
-20.08 %
Jan 1, 2024
87.78 %
-23.78 %
-34.41 %
Jan 1, 2025
-213.46 %
-1,357.31 %
-499.23 %
Jan 1, 2026 (e)
-213.46 %
-38.98 %
-1,782.33 %
Jan 1, 2027 (e)
-213.46 %
-38.98 %
-933.62 %
Jan 1, 2028 (e)
-213.46 %
-38.98 %
-816.33 %

Orexo Stock analysis

What does Orexo do? Orexo AB is a Swedish pharmaceutical company that was founded in 1995 and is headquartered in Uppsala. The company focuses on the development of medications for the treatment of pain and addiction disorders. Business model: Orexo's business model is based on the development of innovative medications and their marketing in the global market. The company specializes in the development of medications based on opioid technology. Divisions: Orexo operates in two main business areas: Pharmaceuticals and digital therapeutics. Pharmaceuticals: In the pharmaceutical division, Orexo is primarily involved in the development of medications used in the treatment of pain and addiction disorders. Some of the best-known medications include: - Zubsolv: a medication for the treatment of opioid addiction - Abstral: a fast-acting pain medication for cancer patients - Edluar: a sleep medication for the treatment of sleep disorders Orexo's pharmaceuticals are distributed in over 60 countries worldwide and have already helped many patients alleviate their symptoms. Digital therapeutics: Orexo has expanded its business model and offers digital therapeutics - apps that contribute to improving the success of pain and addiction disorder treatment. One example is the app "Orexo Digital," which helps patients better monitor their medication and document the progress of their treatment. The app is free and can be downloaded by patients who have been prescribed medications from Orexo. History: Orexo was founded in 1995 by a team of researchers from Uppsala University. The company initially focused on the development of medications for the treatment of inflammatory diseases and allergies. In 2003, the company decided to concentrate on the development of medications in pain and addiction treatment. The first products in this area were the pain medication Abstral and the substitution medication Zubsolv. In the following years, the company grew rapidly and opened additional locations in the United States, United Kingdom, and France. Orexo works closely with key players in the healthcare sector to ensure that its medications are accessible to patients worldwide. Products: Abstral: a medication for the treatment of acute and chronic severe pain. It is taken sublingually and acts quickly. Zubsolv: a medication for the treatment of opioid addiction. It contains the active ingredients buprenorphine and naloxone and can alleviate withdrawal symptoms in opioid addiction. Edluar: a sleep medication for the treatment of sleep disorders. It contains the active ingredient zolpidem and is taken sublingually. Orexo Digital: an app to support patients in the treatment of pain and addiction disorders. It enables the monitoring of treatment progress and provides helpful advice for improving treatment success. Conclusion: Orexo is an innovative pharmaceutical company specializing in the development of medications for the treatment of pain and addiction disorders. The company has made a name for itself with its unique opioid technology and offers successful products such as Abstral and Zubsolv. With its expansion into the field of digital therapeutics, Orexo also demonstrates that it remains at the forefront of technology and innovation. Orexo is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Orexo's EBIT

Orexo's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Orexo's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Orexo's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Orexo’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Orexo stock

EBIT of Orexo is -352.90 M SEK in 2026.

EBIT of Orexo changed from -140.30 M SEK to -352.90 M SEK, representing a 151.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Orexo since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Orexo historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Orexo

All Key Metrics — Orexo